Nature Communications (Mar 2023)

Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates

  • Vincent Pavot,
  • Catherine Berry,
  • Michael Kishko,
  • Natalie G. Anosova,
  • Lu Li,
  • Tim Tibbitts,
  • Dean Huang,
  • Alice Raillard,
  • Sylviane Gautheron,
  • Cindy Gutzeit,
  • Marguerite Koutsoukos,
  • Roman M. Chicz,
  • Valerie Lecouturier

DOI
https://doi.org/10.1038/s41467-023-36908-z
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 8

Abstract

Read online

Waning protective efficacy of mRNA-based booster vaccinations has been observed against newly emerging SARS-CoV-2 variants of concern. In this work, Pavot et al. formulate a monovalent Beta vaccine and demonstrate durable cross-neutralising antibody responses in non-human primates, against a spectrum of variants.